Kenvue Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kirk L. Perry
- Full Time Employees
- 22,000
- Sector
- Consumer non-durables
- Industry
- Household/Personal care
- Address
- 1 Kenvue Way Summit NJ United States 07901
- IPO Date
- May 4, 2023
- CIK
- 0001944048
- Website
- kenvue.com
- Similar Companies
- Business
- Kenvue Inc. Kenvue Inc. (KVUE) operates as the world's largest pure-play consumer health company by revenue, focusing on science-backed everyday care products that serve over 1.2 billion people daily across more than 100 countries including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. The company manages three core segments: Self Care, offering cough, cold and allergy remedies, pain care, digestive health, smoking cessation, eye care, and related products under brands such as Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSL, Rhinocort, Calpol, and Zyrtec; Skin Health and Beauty, providing face and body care, hair, sun, and other solutions via Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX; and Essential Health, encompassing oral care, baby care, women’s health, wound care, and other items through Listerine, Johnson’s, Band-Aid, Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash. Incorporated in 2022 as a spin-off from Johnson & Johnson Johnson & Johnson and headquartered in Summit, New Jersey, Kenvue draws on a heritage exceeding 135 years in consumer health innovation. In November 2025, Kimberly-Clark Corporation Kimberly-Clark Corporation agreed to acquire Kenvue in a $48.7 billion cash-and-stock transaction valued at approximately $21.01 per share, representing a 33% premium to recent trading levels and creating a combined consumer health and wellness entity with projected $2.1 billion in annual synergies by 2028, subject to regulatory approvals expected in the second half of 2026. Earlier in 2025, Kenvue opened its new 290,000-square-foot global headquarters in Summit, New Jersey, featuring a 100,000-square-foot Science and Innovation Lab to consolidate operations, accelerate R&D, and enhance proximity to talent and consumers; launched the Tylenol Proactive Support supplement line for joint care; initiated the Total Quit campaign advocating tobacco and nicotine regulation; and appointed Kirk Perry as permanent CEO following a strategic review amid leadership transitions.
Company News
The Dividend Portfolio That Covers Your Required Minimum Distribution Without Selling a Share: KMB, BIZD, and SPHD
Can Kimberly-Clark's Kenvue Acquisition Unlock Long-Term Growth?
Kimberly-Clark Corporation Announces Expiration and Final Results of Exchange Offers for Kenvue Notes
Kimberly-Clark Acquires Kenvue. Here's What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.
Kenvue Is Leaving the S&P 500: Here's What It Means for Investors
Kimberly-Clark Completes Acquisition of Kenvue, Creating the Preeminent Global Consumer Health and Wellness Leader
Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Kenvue (KVUE) Surpasses Q3 Earnings Estimates
4 Dividend Stocks Yielding at Least 4.35% Across 4 Different Businesses
Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
Kenvue Reports Third Quarter 2026 Results
Kenvue's Q3 Earnings on the Horizon: Key Insights for Investors
Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes
4 Big-Name Dividend Stocks Paying Yields Most Blue Chips Can't Match
Kimberly-Clark: The Dividend Survives Kenvue, But Expect Token Raises
3 Beauty Stocks to Explore as Consumer Preferences Reshape the Market
Kenvue to Announce Third Quarter 2026 Results on October 30, 2026
October's 5 Dividend Growth Stocks With Yields Up To 7.99%
First Citizens Bank & Trust Co. Purchases New Position in Kenvue Inc. $KVUE
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up